New pharmacotherapy options for hyperphosphatemia

Ryan Stormont, Ryan McCoy, Khalid Bashir, Mark A. Malesker

Research output: Contribution to specialist publicationArticle

Abstract

Hyperphosphatemia is an abnormally high level of serum phosphate that contributes to chronic kidney disease (CKD). The management of hyperphosphatemia has included dietary phosphate restriction and use of phosphate binders. The first phosphate binders were aluminum- and magnesium-based antacids. Adverse effects and toxicity limited the use of these agents, and therapy evolved with calcium carbonate, calcium acetate, sevelamer, and lanthanum carbonate. Recently, two iron-based phosphate binders have been approved. Hyperphosphatemia in CKD stages 1 to 3 can typically be controlled with dietary changes. Calcium-based products are often started in stage 4 secondary to efficacy, safety, and cost. In CKD stage 5, hypercalcemia can increase the risk of cardiovascular disease. In this situation, sevelamer and lanthanum have demonstrated a cardiovascular mortality benefit. Sucroferric oxyhydroxide and ferric citrate are calcium-free and may offer benefits in those with a high pill burden and in patients with concurrent anemia, respectively.

Original languageEnglish
PagesHS18-HS
Volume41
No3
Specialist publicationU.S. Pharmacist
StatePublished - Mar 1 2016

Fingerprint

Hyperphosphatemia
Drug therapy
Phosphates
Drug Therapy
Chronic Renal Insufficiency
Binders
calcium acetate
Calcium Carbonate
Calcium
Lanthanum
Antacids
Hypercalcemia
Aluminum
Magnesium
Toxicity
Anemia
Cardiovascular Diseases
Iron
Safety
Costs and Cost Analysis

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science
  • Pharmacology
  • Pharmacy

Cite this

New pharmacotherapy options for hyperphosphatemia. / Stormont, Ryan; McCoy, Ryan; Bashir, Khalid; Malesker, Mark A.

In: U.S. Pharmacist, Vol. 41, No. 3, 01.03.2016, p. HS18-HS.

Research output: Contribution to specialist publicationArticle

Stormont, R, McCoy, R, Bashir, K & Malesker, MA 2016, 'New pharmacotherapy options for hyperphosphatemia' U.S. Pharmacist, vol. 41, no. 3, pp. HS18-HS.
Stormont, Ryan ; McCoy, Ryan ; Bashir, Khalid ; Malesker, Mark A. / New pharmacotherapy options for hyperphosphatemia. In: U.S. Pharmacist. 2016 ; Vol. 41, No. 3. pp. HS18-HS.
@misc{da8412347c2847b88a10dc5ec35ef5ac,
title = "New pharmacotherapy options for hyperphosphatemia",
abstract = "Hyperphosphatemia is an abnormally high level of serum phosphate that contributes to chronic kidney disease (CKD). The management of hyperphosphatemia has included dietary phosphate restriction and use of phosphate binders. The first phosphate binders were aluminum- and magnesium-based antacids. Adverse effects and toxicity limited the use of these agents, and therapy evolved with calcium carbonate, calcium acetate, sevelamer, and lanthanum carbonate. Recently, two iron-based phosphate binders have been approved. Hyperphosphatemia in CKD stages 1 to 3 can typically be controlled with dietary changes. Calcium-based products are often started in stage 4 secondary to efficacy, safety, and cost. In CKD stage 5, hypercalcemia can increase the risk of cardiovascular disease. In this situation, sevelamer and lanthanum have demonstrated a cardiovascular mortality benefit. Sucroferric oxyhydroxide and ferric citrate are calcium-free and may offer benefits in those with a high pill burden and in patients with concurrent anemia, respectively.",
author = "Ryan Stormont and Ryan McCoy and Khalid Bashir and Malesker, {Mark A.}",
year = "2016",
month = "3",
day = "1",
language = "English",
volume = "41",
pages = "HS18--HS",
journal = "U.S. Pharmacist",
issn = "0148-4818",
publisher = "Jobson Publishing Corporation",

}

TY - GEN

T1 - New pharmacotherapy options for hyperphosphatemia

AU - Stormont, Ryan

AU - McCoy, Ryan

AU - Bashir, Khalid

AU - Malesker, Mark A.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Hyperphosphatemia is an abnormally high level of serum phosphate that contributes to chronic kidney disease (CKD). The management of hyperphosphatemia has included dietary phosphate restriction and use of phosphate binders. The first phosphate binders were aluminum- and magnesium-based antacids. Adverse effects and toxicity limited the use of these agents, and therapy evolved with calcium carbonate, calcium acetate, sevelamer, and lanthanum carbonate. Recently, two iron-based phosphate binders have been approved. Hyperphosphatemia in CKD stages 1 to 3 can typically be controlled with dietary changes. Calcium-based products are often started in stage 4 secondary to efficacy, safety, and cost. In CKD stage 5, hypercalcemia can increase the risk of cardiovascular disease. In this situation, sevelamer and lanthanum have demonstrated a cardiovascular mortality benefit. Sucroferric oxyhydroxide and ferric citrate are calcium-free and may offer benefits in those with a high pill burden and in patients with concurrent anemia, respectively.

AB - Hyperphosphatemia is an abnormally high level of serum phosphate that contributes to chronic kidney disease (CKD). The management of hyperphosphatemia has included dietary phosphate restriction and use of phosphate binders. The first phosphate binders were aluminum- and magnesium-based antacids. Adverse effects and toxicity limited the use of these agents, and therapy evolved with calcium carbonate, calcium acetate, sevelamer, and lanthanum carbonate. Recently, two iron-based phosphate binders have been approved. Hyperphosphatemia in CKD stages 1 to 3 can typically be controlled with dietary changes. Calcium-based products are often started in stage 4 secondary to efficacy, safety, and cost. In CKD stage 5, hypercalcemia can increase the risk of cardiovascular disease. In this situation, sevelamer and lanthanum have demonstrated a cardiovascular mortality benefit. Sucroferric oxyhydroxide and ferric citrate are calcium-free and may offer benefits in those with a high pill burden and in patients with concurrent anemia, respectively.

UR - http://www.scopus.com/inward/record.url?scp=84961239329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961239329&partnerID=8YFLogxK

M3 - Article

VL - 41

SP - HS18-HS

JO - U.S. Pharmacist

JF - U.S. Pharmacist

SN - 0148-4818

ER -